Imaging agent may improve diagnoses for rare heart disease
A PET/CT radiotracer demonstrated high sensitivity and specificity for diagnosing cardiac amyloidosis, a rare disease that causes abnormal protein buildup in the heart and heart failure, according to a recent clinical trial published in JAMA.
A new radiotracer, iodine-124-evuzamitide, has shown promising results in diagnosing cardiac amyloidosis, a rare disease that causes abnormal protein buildup in the heart and leads to heart failure. The findings, published in JAMA, indicate that evuzamitide could be a valuable addition to diagnostic tools when standard imaging tests are inconclusive.
In a phase III clinical trial involving 170 patients at 18 U.S. medical centers, evuzamitide demonstrated high sensitivity (94%) and specificity (86%) in diagnosing both transthyretin amyloidosis and immunoglobulin light chain amyloidosis. The radiotracer works by binding directly to amyloid fibrils, allowing for clearer diagnoses when standard imaging methods are ambiguous.
However, further research is needed to determine the best way to integrate evuzamitide into clinical workflows.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
